We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


BioServe Acquires Genomics Collaborative from SeraCare

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioServe Acquires Genomics Collaborative from SeraCare"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

BioServe has announced that it has acquired Genomics Collaborative from SeraCare Life Sciences, Inc.

Genomics Collaborative facilitates biomarker discovery and validation through its Global Repository®, a library of 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients collected on four continents.

Through this acquisition BioServe expands its pre-clinical product and service capabilities to provide organizations engaged in drug discovery and diagnostic development with a biomaterial to validated data services platform.

The service platform extends from molecular research products and services such as DNA and RNA purification reagents, DNA sequencing, oligonucleotide synthesis and genotyping to ready-made large epidemiologically sound case-control studies of inflammatory disorders, endocrine disorders, cardiovascular disease, diabetes, hypertension, obesity and cancers including breast, prostate, lung and colorectal.

"The acquisition of Genomics Collaborative firmly positions BioServe as a preferred partner for pre-clinical discovery and validation studies. Working with BioServe, drug discovery researchers have the flexibility to tap the Bio Repository to augment their in house sample sets, design entire genomic studies around our sample library, and further benefit from BioServe's proven ability to process and analyze vast quantities of genomic content," said Rama Modali, President, BioServe.

He continued, "BioServe's complete biomaterial to validated data approach will help researchers identify the genetics markers, biochemical pathways and drug targets that cause disease to accelerate the development of new and safer drugs."

BioServe will continue to offer the GCI Access program™, which allows researchers around the world to access human DNA, RNA, serum and tissue samples with comprehensive informed consent and detailed clinical data, on a fee for service basis.

Genomics Collaborative will operate as a fully integrated division of BioServe, offering its DNA, tissue and serum Global Repository® samples to BioServe's customers worldwide.

The Genomics Collaborative clinical team, led by Vice President of Medical Affairs, George Taylor MD, has joined BioServe and will further add to the company's expertise in genomics, epidemiology, biostatistics and molecular biology.